Carsten C G, Calton W C, Johanning J M, Armstrong P J, Franklin D P, Carey D J, Elmore J R
Section of Vascular Surgery and Sigfried and Janet Weis Center for Research, Geisinger Health System, Danville, Pa 17822-2150, USA.
J Vasc Surg. 2001 Jun;33(6):1255-62. doi: 10.1067/mva.2001.112706.
Research investigating abdominal aortic aneurysms (AAAs) commonly uses a rat model dependent on aortic infusion of porcine pancreatic elastase to initiate AAA formation. Unfortunately, the sizes of AAAs generated by this model have varied widely among published studies. This may reflect lot-to-lot variations in commercial elastase preparations. This study was undertaken to investigate the ability of different lots of elastase to induce AAAs and explain the variability identified.
Four lots of elastase were evaluated in the standard rat AAA model. Saline solution was used as a control. Additional groups of rats were treated with higher concentrations of elastase with or without the macrophage activator thioglycollate medium. Aortic diameters were measured in all rats. Inflammation and elastin degradation was examined histologically. Elastase activity and purity were evaluated for all lots.
Of the four lots tested, only one was able to consistently generate AAAs at the standard dose (P <.05). Increasing the amount of elastase infused produced AAAs in some ineffective lots. Infusion of thioglycollate medium in combination with otherwise ineffective elastase produced AAAs (P =.02). However, the elastase with the highest purity failed to generate AAAs, even at the highest dose tested or in combination with thyioglycollate medium. Thioglycollate medium alone failed to result in AAA formation. All elastase lots displayed elastolytic activity in vitro and produced elastin degradation in vivo. Elastin degradation did not correlate with AAA size in elastase-treated rats (P = NS). Aneurysm size correlated with extent of inflammation (P =.005).
Induction of AAAs does not correlate with elastolytic activity. Infusion of pure elastase alone is not sufficient to induce AAA formation in spite of evidence of elastin degradation. Presumed inflammatory modifiers, which contaminate some elastase preparations, enhance AAA formation. Future use of this rat model will need to take the variability of elastase preparations into account with controls for each new elastase lot.
研究腹主动脉瘤(AAA)的研究通常使用依赖于向主动脉注入猪胰弹性蛋白酶来引发AAA形成的大鼠模型。不幸的是,该模型所产生的AAA大小在已发表的研究中差异很大。这可能反映了商业弹性蛋白酶制剂的批次间差异。本研究旨在调查不同批次的弹性蛋白酶诱导AAA的能力,并解释所发现的变异性。
在标准大鼠AAA模型中评估了四批弹性蛋白酶。使用盐溶液作为对照。另外几组大鼠用更高浓度的弹性蛋白酶进行处理,同时添加或不添加巨噬细胞激活剂巯基乙酸盐培养基。测量所有大鼠的主动脉直径。通过组织学检查炎症和弹性蛋白降解情况。对所有批次的弹性蛋白酶活性和纯度进行了评估。
在测试的四批弹性蛋白酶中,只有一批能够在标准剂量下持续产生AAA(P <.05)。增加注入的弹性蛋白酶量在一些无效批次中产生了AAA。将巯基乙酸盐培养基与原本无效的弹性蛋白酶联合注入产生了AAA(P =.02)。然而,纯度最高的弹性蛋白酶即使在测试的最高剂量下或与巯基乙酸盐培养基联合使用时也未能产生AAA。单独使用巯基乙酸盐培养基未能导致AAA形成。所有批次的弹性蛋白酶在体外均表现出弹性蛋白分解活性,并在体内导致弹性蛋白降解。在弹性蛋白酶处理的大鼠中,弹性蛋白降解与AAA大小无关(P =无显著性差异)。动脉瘤大小与炎症程度相关(P =.005)。
AAA的诱导与弹性蛋白分解活性无关。尽管有弹性蛋白降解的证据,但单独注入纯弹性蛋白酶不足以诱导AAA形成。一些弹性蛋白酶制剂中含有的假定炎症调节剂会增强AAA的形成。未来使用该大鼠模型时需要考虑弹性蛋白酶制剂的变异性,并对每一批新的弹性蛋白酶进行对照。